Proteus Syndrome Market Insight, Epidemiology and Market Forecast - 2034The Proteus Syndrome market is entering a pivotal decade, driven by ...

Enterprises will not see immediate impact from the AI Action Plan, but it signals wider support for open-source models and evaluations.

Each year, 1·3 million people die from viral hepatitis, and mortality is increasing.1 This World Hepatitis Day, all stakeholders must break down the barriers to hepatitis elimination, including ending ...

Hepatitis B virus, a killer of more than one million people each year, is a notoriously wily virus, often lingering and ...

Get all latest & breaking news on Corona Remedies. Watch videos, top stories and articles on Corona Remedies at moneycontrol.com.

Hepatitis B virus, a killer of more than one million people each year, is a notoriously wily virus, often lingering and resurfacing even ...

(Alliance News) - GSK PLC on Wednesday said the US Food & Drug Administration has extended the review period for Blenrep combinations in relapsed/refractory multiple myeloma after an advisory ...

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug, Blenrep, as a combination treatment ...

Ozzy Osbourne has been remembered as a “pioneer,” a “fearless talent” and a “dear friend,” in an outpouring of tributes from ...

GSK said the U.S. Food and Drug Administration extended its review period for Blenrep combinations to treat patients with relapsed or refractory multiple myeloma.

GSK PLC GSK shares rose 1.78% to £13.72 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.42% to 9,061.49. GSK PLC ...